Document 0873
 DOCN  M9550873
 TI    Nucleoside reverse transcriptase inhibitors and resistance of human
       immunodeficiency virus type 1.
 DT    9505
 AU    Johnson VA; Department of Medicine, University of Alabama at Birmingham;
       35294-0006.
 SO    J Infect Dis. 1995 Mar;171 Suppl 2:S140-9. Unique Identifier : AIDSLINE
       MED/95164990
 AB    Drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1)
       emerge during long-term treatment with nucleoside reverse transcriptase
       inhibitors, such as zidovudine. The clinical significance of in vitro
       drug resistance to zidovudine has been difficult to determine. However,
       in a virologic analysis of baseline specimens from the AIDS Clinical
       Trials Group (ACTG) 116B/117 study, high-level zidovudine resistance,
       defined as an IC50 of > or = 1 microM at study entry, was significantly
       associated with clinical disease progression. High-level zidovudine
       resistance also was an independent predictor of death as an end point,
       although this finding does not imply a direct causal effect. Duration
       and cumulative dose of prior zidovudine therapy did not predict clinical
       disease progression. More potent antiretroviral agents are needed that
       can be used in combination to achieve more complete virus suppression
       and to reduce the selection of drug-resistant HIV-1 mutants.
 DE    Clinical Trials  Didanosine/THERAPEUTIC USE
       Dideoxynucleosides/*THERAPEUTIC USE  Drug Resistance  Human  HIV
       Infections/*DRUG THERAPY  HIV-1/*DRUG EFFECTS  Support, Non-U.S. Gov't
       Support, U.S. Gov't, Non-P.H.S.  Support, U.S. Gov't, P.H.S.
       Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).